Q-omics provides the consensus-scored BTBD7P1 profile across patient tissues and cancer cell-line models. BTBD7P1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, BTBD7P1 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, BTBD7P1 RNA expression shows 13,192 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, KICH, and TGCT as cancer lineages where BTBD7P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BTBD7P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BTBD7P1 survival associations across molecular data types. BTBD7P1 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BTBD7P1 RNA expression–survival associations across cancer types. High BTBD7P1 expression shows unfavorable associations in LGG and CESC, but favorable associations in LUAD, ACC, KIRC and MESO. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .005). Together, the overview and detailed table identify LUAD as the clearest survival context for BTBD7P1 RNA expression.
This table summarizes BTBD7P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for BTBD7P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BTBD7P1 shows lower tumor expression in KICH and BRCA and higher tumor expression in LIHC, LUSC, LUAD and STAD. The KICH box plot shows higher BTBD7P1 RNA expression in normal versus tumor tissue (log2 FC = −0.256, t-test p < 0.001).
This table shows molecular features associated with BTBD7P1 in patient tissues and cancer cell lines. In patient samples, BTBD7P1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
